There is a detail about severe burn injuries that rarely makes it into news coverage but shapes the rest of a survivor's life: you cannot sweat where the skin has been destroyed. This sounds, at first, like a minor inconvenience sitting in the shadow of pain, disfigurement, and years of reconstruction. In practice it is far more serious than that. The human body has somewhere between two and four million sweat glands embedded in skin across nearly every surface, and their job, cooling the body through evaporative perspiration, is so essential to survival that a person who loses sweat function over large areas of their body cannot safely exercise, tolerate a warm afternoon, or manage a fever the way the rest of us do. They carry thermometers when they go outdoors. They time their days around shade.
Traditional skin grafts, which have been the standard of care for severe burn injuries for decades, solve one problem while leaving this one entirely untouched. They cover the wound, prevent infection, and allow scar tissue to stabilise , but they bring no sweat glands with them. The replaced skin is, in functional terms, incomplete. Surgeons have long known this. Patients have long lived with it. And researchers in regenerative medicine have long listed it as one of the field's most stubborn unsolved problems, because sweat glands, once destroyed in a full-thickness burn, simply do not regenerate on their own.
That picture is now changing. Work published through EurekAlert and the journal Science Bulletin describes how researchers have developed a non-genetic chemical method to reprogram ordinary human skin cells into functional sweat gland cells, and how those cells, when transplanted into damaged skin in animal models, restored genuine thermoregulatory sweating. Meanwhile, researchers in California associated with the Stanford Institute of Regenerative Medicine have pursued parallel work using precision bioprinting of layered skin structures grown from pluripotent stem cells, structures that include working sweat glands, early blood vessel networks, and in some configurations, hair follicles. These two strands of research, arriving at the same destination from different directions, together signal that the problem of the missing sweat gland is on the verge of being solved.
Understanding what makes sweat gland regeneration difficult requires a brief tour of what sweat glands actually are and what makes them structurally distinct from surrounding skin tissue. Each gland is a coiled tubular structure that descends from the epidermis into the deeper dermis, secreting sweat through a duct that opens at a pore on the skin's surface. The gland wall is lined with secretory cells that pull water and electrolytes from surrounding blood vessels and push them outward in response to signals from the sympathetic nervous system. They also produce antimicrobial peptides that help defend the skin against bacterial colonisation, a function that matters enormously in burned patients whose primary skin barrier has already been compromised.
The deep structural problem is that sweat glands, unlike the outer epidermis, do not naturally regenerate after full-thickness destruction. Research published on PubMed has confirmed for years that when a deep burn destroys the dermis, the regenerated or grafted skin that closes the wound is essentially devoid of gland structures. The healed tissue is biologically simpler than what it replaced, a patch rather than a restoration. Engineers and biologists trying to build replacement skin in the laboratory have hit this same wall: it is straightforward to grow sheets of keratinocytes, the cells of the outer epidermis, but recreating the three-dimensional architecture of a gland embedded within layered tissue is a fundamentally harder problem.
The additional challenge is innervation. Sweat glands are controlled by nerve fibres, and a gland grown in a dish has no connection to the nervous system. Even if transplanted successfully, it might sit inert, structurally present but physiologically silent, because no nerve signal ever reaches it. The California research, and the parallel work published in Science Bulletin, both addressed this: in both cases, transplanted cells were observed forming new connections to surrounding nerve fibres and blood vessels, a finding that distinguishes this generation of work from earlier attempts at skin bioengineering.
The approach that has attracted the most attention among researchers working on sweat gland regeneration involves chemical reprogramming, a technique that uses small molecules rather than genetic modification to change what a cell is programmed to do. The research team behind the Science Bulletin study identified a combination of six specific chemicals that, when applied to ordinary human epidermal keratinocytes, the most abundant cells in the outer skin layer, pushed those cells across a biological threshold, converting them into cells that behave like sweat gland secretory cells. These converted cells were named chemically induced sweat gland cells, or ciSGCs.
Using six precisely sequenced small molecules, researchers converted ordinary human epidermal keratinocytes into sweat gland cells (ciSGCs) without altering the cells' DNA. When transplanted into burn-damaged mouse skin, ciSGCs accelerated wound healing, restored dermal architecture, and produced fully functional sweat glands with nerve and blood vessel connections.
Laboratory tests confirmed ciSGCs could self-renew and differentiate into sweat-secreting cells while producing the same key marker proteins found in natural glands, including CEA, cytokeratin 8, and cytokeratin 14.
Source: Science Bulletin, November 2024 · DOI: 10.1016/j.scib.2024.11.003 · Via EurekAlert (AAAS)
The significance of using chemistry rather than genetics is not just technical, it matters enormously for the path toward clinical use. Genetic modification of human cells raises safety questions that are difficult and slow to resolve, including the risk that inserting or altering genetic material could disrupt the regulation of cell growth and contribute to cancer. Chemical reprogramming sidesteps those concerns entirely because it changes what a cell does without changing its underlying DNA. The process is also potentially scalable: a hospital's cell culture laboratory could in principle expand a patient's own keratinocytes, expose them to the chemical cocktail, and generate a supply of personalised sweat gland cells matched to the patient's own immune profile, reducing the risk of rejection.
The Stanford bioprinting approach works differently but arrives at compatible results. Starting from pluripotent stem cells, cells that have the capacity to become any tissue in the body, researchers used precisely timed growth factor protocols to guide differentiation along a skin developmental pathway. Bioprinting technology then assembled the resulting cells into layered structures that replicate the architecture of real skin: an outer epidermal layer, a deeper dermal layer with structural collagen-like scaffolding, and embedded gland structures positioned at the correct depth. Some versions of these constructs have also incorporated early vascular networks, the scaffolding that allows blood vessels to grow in, keeping the tissue alive after transplantation.
The clinical picture for a burn survivor who has lost sweat gland function across a significant portion of their body surface is well documented in the medical literature, and it is sobering. The World Health Organization estimates that burns cause approximately 180,000 deaths annually and that non-fatal burns are a leading cause of long-term disability and disfigurement globally. Beyond the immediate crisis, survivors face a secondary burden that the healthcare system is only beginning to quantify: the loss of thermoregulatory capacity turns ordinary warm weather into a medical risk.
The body's core temperature is normally held within a very narrow range, and sweating is the primary tool for offloading excess heat during physical exertion or exposure to warm environments. A person who cannot sweat over 30 or 40 percent of their body surface is operating with significantly reduced capacity to regulate their temperature. This translates into a heightened risk of heat exhaustion and heat stroke, a chronic need to avoid exercise and outdoor heat, disrupted sleep in warm seasons, and a profound loss of the kind of physical normalcy that most people take for granted. Burn survivors describe timing errands around cooler parts of the day, avoiding travel to warm climates, and carrying cooling devices. The psychological weight of these accommodations on top of everything else that burn recovery demands is difficult to overstate.
Faster wound closure with bioengineered regenerative skin versus traditional autografting, per tissue engineering trial data.
Sweat glands in the average adult human body, distributed across nearly every skin surface.
Mean total healthcare cost per burn patient, per a systematic review, highlighting the economic urgency of better treatments.
Compound annual growth rate of the global regenerative artificial skin market, projected through 2034.
The burns segment carries a disproportionate burden at the population level. Global Burden of Disease data puts total global burn cases at roughly nine million per year, with the majority falling in low and middle-income countries where access to specialised burn centres is limited and long-term rehabilitation is rarely available. The economic losses associated with burn injuries, measured in disability-adjusted life years and lost productivity, were estimated at $112 billion globally by a Harvard-affiliated team publishing in Plastic and Reconstructive Surgery in 2024. That figure underscores why even incremental improvements in treatment quality, such as grafts that allow patients to sweat, have outsized value: a survivor who can tolerate physical work in a warm environment has a fundamentally different economic prognosis than one who cannot.
It is worth understanding just how long researchers have been chasing this problem to appreciate how significant the current work is. The first generation of bioengineered skin substitutes, products like Integra and Apligraf, became available in the 1990s and represented a genuine advance over nothing, they provided structural scaffolding for wound closure and helped reduce the need for donor skin harvested from elsewhere on the patient's body. But they were fundamentally two-dimensional constructs, sheets of cells without glandular architecture. They could not sweat. They could not produce sebum. And they could not reconnect to nerves or fully integrate with surrounding vasculature.
Researchers at the California Institute for Regenerative Medicine documented as far back as 2016 that existing artificial skin forced burn victims to apply oils constantly to prevent grafted areas from drying out, because without sebaceous glands there was no natural lubrication. The lack of sweat glands meant graft regions could not regulate temperature. The disruption of nerve fibres meant the sense of touch was often lost. The emotional consequences were real too, grafted skin frequently failed to match the surrounding skin's tone and texture, leaving survivors visibly marked in ways that added psychological burden to physical disability.
The breakthrough work from Japan's RIKEN Center for Developmental Biology, published around the same time, demonstrated that complex skin tissue could be grown from induced pluripotent stem cells, complete with hair follicles and sebaceous glands, and implanted into mouse skin where it formed connections with host nerve fibres and muscle tissue. That work was celebrated as a proof of concept but was openly acknowledged as being years away from human application. A decade on, the field has moved considerably closer. What was a proof of concept in a mouse model has become a chemically reproducible protocol that works with human cells and has been validated in transplantation experiments.
| Feature | Chemical Reprogramming (ciSGC) | Stem Cell Bioprinting | Traditional Skin Graft |
|---|---|---|---|
| Sweat gland function | ✔ Restored | ✔ Incorporated | ✘ Absent |
| Nerve reconnection | ✔ Observed in models | ✔ Partially achieved | ✘ Rarely achieved |
| DNA modification required | ✔ None | Minimal (iPSC) | ✔ None |
| Donor skin required | ✘ Not required | ✘ Not required | ✔ Required |
| Personalisation | High — uses patient's own cells | High — stem cell lines | High if autograft |
| Scale of production | Potentially scalable | Limited by bioprinter throughput | Limited by donor site |
| Current stage | Pre-clinical (animal models) | Pre-clinical (lab and animal) | Standard clinical care |
Neither approach is ready for routine clinical use today. Both are at the pre-clinical stage, meaning they have been validated in laboratory conditions and animal models but have not yet been tested in human patients through the structured trial phases that regulatory agencies require before approval. That path, from promising pre-clinical results to an approved therapy that a burn surgeon can order, typically takes a decade or more and involves Phase I safety trials, Phase II efficacy studies, and Phase III larger-scale comparisons against existing standard of care. For patients living with the consequences of burns right now, that timeline is painful. For the field, however, it represents genuine and accelerating progress rather than stalled hope.
One of the more illuminating aspects of the current research wave is how much more clearly it has defined what "fully functional skin" actually means. The popular understanding tends to focus on appearance, does the skin look right, does it match the surrounding tissue, does it cover the wound cleanly? But the functional definition that drives the California research is considerably more demanding.
Truly functional replacement skin needs to perform thermoregulation through sweating. It needs to produce sebum to maintain the barrier against moisture loss. It needs to be innervated, connected to sensory nerve fibres that allow the patient to feel touch, pressure, temperature, and pain in the affected area. It needs to be vascularised, supplied by blood vessels that keep it alive and support the immune response against pathogens. Ideally it also needs to contain hair follicles, which anchor the skin structurally and contribute to temperature regulation and sensory function. And all of this needs to happen without triggering the immune rejection that has plagued allografts for as long as transplant medicine has existed.
"Without the replacement of sweat glands and hair follicles within the skin tissue, graft regions do not adequately regulate body temperature, and the sense of touch is often lost as disrupted nerve fibres fail to reconnect."
California Institute for Regenerative Medicine (CIRM) Research Commentary
The ciSGC approach addresses the thermoregulatory piece directly, it literally restores sweating, while the neural reconnection observed in transplantation experiments addresses the sensory piece. The bioprinting approach targets the architectural complexity: by assembling the right cells in the right three-dimensional arrangement before transplantation, it gives the body a structural template that incoming blood vessels and nerve fibres can follow. Both approaches are addressing real functional gaps in ways that earlier generations of skin substitutes did not even attempt.
1990s
First Generation Skin Substitutes
Products like Integra dermis regeneration template and Apligraf bilayered living skin construct entered clinical use, covering wounds but lacking glands, nerves, and vascular architecture.
2016
Stem Cell Skin Organoids — Proof of Concept
RIKEN researchers in Japan demonstrated that iPSC-derived skin tissue, grown in laboratory settings, could form hair follicles, sebaceous glands, and nerve connections when transplanted into mouse models, the first true three-dimensional skin organ grown from stem cells.
2024
Chemical Reprogramming Achieves Sweat Restoration
Researchers published the ciSGC protocol in Science Bulletin, demonstrating that six small molecules could convert human keratinocytes into functional sweat gland cells, restoring thermoregulatory sweating in burned mouse skin without genetic modification.
2024–2025
California Bioprinting Advances
Stanford Institute of Regenerative Medicine and related California research groups refined bioprinted skin constructs incorporating sweat glands, blood vessel precursors, and hair follicles, moving toward pre-IND (Investigational New Drug) regulatory consultations.
Projected 2027–2029
Phase I Human Safety Trials
If current pre-clinical momentum holds, first-in-human safety trials for ciSGC-based or bioprinted skin therapies could begin in this window, initially in patients with the most severe burns where the risk-benefit calculation favours early adoption.
Projected 2030s
Possible Regulatory Approval and Clinical Adoption
Full clinical availability for burn centres, contingent on Phase II and III trial success, manufacturing scale-up, and regulatory approval from agencies including the FDA.
It would be naive to discuss this research without acknowledging the access question. Burn injuries are not distributed equally. WHO data indicates that the overwhelming majority of burn deaths occur in low and middle-income countries, where most occur in domestic settings, cooking fires, kerosene lamps, electrical accidents in under-resourced homes. The populations carrying the highest burden of burns are often the furthest from the specialised care that any advanced therapy requires.
Advanced bioengineered skin, at least in its early iterations, will almost certainly be expensive. The global skin graft market was valued at $418 million in 2025 and is growing, but the high-end bioengineered segment commands prices that put it beyond reach for most healthcare systems outside wealthy countries. The chemical reprogramming approach offers a somewhat more optimistic access scenario: if the ciSGC protocol can be standardised and manufactured at scale, the per-unit cost could fall over time in the way that many biological therapies have once manufacturing efficiencies are established. But this will require deliberate effort by health agencies, non-governmental organisations, and pharmaceutical companies to ensure that the benefits of this research reach the places that need them most.
There is also the question of who benefits within the population of burn survivors. Patients with the most severe injuries, those with burns covering 40 percent or more of body surface area, stand to gain the most from functional skin that can regulate temperature, because their compensatory mechanisms are most compromised. But these are also the patients for whom transplantation is most medically complex and whose immune systems may be most stressed. The first clinical applications will need to carefully calibrate risk and benefit, and regulatory agencies will require extensive safety data before approving any novel cell-based therapy.
Researchers are careful to note that the potential applications of this technology extend well beyond burn care, although burn victims represent the most urgent and clearly defined patient population. Diabetic patients with chronic wounds and compromised skin often lack adequate glandular function in affected areas. People with genetic skin conditions that impair sweat gland development suffer from the same thermoregulatory risks as burn survivors. The cosmetic surgery and plastic surgery fields are watching developments in bioengineered skin closely, since better skin substitutes would improve outcomes in reconstructive procedures following cancer excision, trauma, and congenital anomalies.
There is also a long-term scientific interest in what this technology tells us about cellular plasticity, the capacity of cells to change identity and function. The ciSGC work demonstrates that a fully differentiated adult human cell can be pushed into a new functional identity using chemical signals alone. That finding has implications across regenerative medicine, because it suggests that the reprogramming toolkit that works for sweat gland cells might, with modification, be adapted for other glandular tissues that currently resist regeneration.
The drug testing and toxicology sectors have already signalled interest in lab-grown skin for an entirely different reason: having reliable, reproducible human skin that responds to chemicals the way real skin does would dramatically improve the accuracy of cosmetic and pharmaceutical safety testing, reducing reliance on animal models. A skin construct that includes functional glands adds another layer of physiological realism to those tests, making results more predictive of what happens in actual human patients.
The language researchers use when describing this work is noticeably measured. The teams behind the ciSGC study describe it as a "non-genetic reprogramming method" that offers a "safe, scalable, and highly adaptable" route to clinical application, careful phrasing that acknowledges the distance between a result in a mouse model and a treatment available to patients. The Stanford-affiliated California researchers are similarly cautious, noting that bioprinting technology still faces challenges in producing constructs at the size and consistency needed for clinical grafting, and that vascularisation, ensuring the printed skin can develop a blood supply after transplantation, remains one of the most technically demanding aspects of the work.
What is notable, however, is the convergence. Multiple independent research groups, using different technical approaches, are arriving at the same destination from different directions. Chemical reprogramming, stem cell bioprinting, organoid development from pluripotent cells, gene-activated scaffolds, all of these threads are moving toward the same goal of skin that is not just a covering but a functioning organ system. When multiple methodologies begin solving the same problem simultaneously, it often signals that the underlying science has matured to the point where clinical translation is a matter of engineering and regulatory pathway rather than fundamental biological discovery. That is where burn care appears to be heading.
For the millions of people living with the aftermath of severe burns, news of laboratory breakthroughs can be a complicated thing to process. There have been promising announcements before, and the gap between a result in a research paper and a treatment in a hospital has a way of stretching. Burn survivors and their families have learned, often through painful experience, to hold hope at a careful distance.
What makes the current moment feel different to researchers in the field is not any single study but the maturation of the entire ecosystem around it. Manufacturing capability has improved. Regulatory frameworks for cell-based therapies have become more clearly defined. The understanding of how to guide stem cell differentiation has deepened considerably. The specific biological target, the sweat gland, its structure, its markers, its developmental pathway, is now understood in enough detail to be deliberately recreated. These are the conditions under which a technology transitions from a curiosity to a treatment.
The full journey from a California laboratory to a burn unit is not short. But for the first time, it is possible to look at that journey and see a plausible route all the way to the destination, a day when a patient recovering from severe burns receives skin that does not just close the wound but restores something closer to the life they had before.
That would be worth the wait.
0 Comments